Clinical Trials › NCT06220201
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 120
Target enrollment
14
U.S. states
Mar 2024
Start date
Jul 2027
Expected completion
Interventions / Treatments
CC-97540FludarabineCyclophosphamide
Conditions studied
Multiple Sclerosis
Where this trial is running (17 sites)
Colorado2 sites
Aurora · Denver
New York2 sites
New York · New York
Ohio2 sites
Cincinnati · Cleveland
Alabama1 site
Birmingham
California1 site
Irvine
Connecticut1 site
New Haven
Kansas1 site
Kansas City
Louisiana1 site
New Orleans
Massachusetts1 site
Boston
Missouri1 site
St Louis
New Jersey1 site
Hackensack
Oregon1 site
Portland
Washington1 site
Seattle
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (11)
UCI Health Multiple Sclerosis Program
Orange, CA
Orange, CA
Swedish Neuroscience Institute MS Center
Seattle, WA
Seattle, WA
John L. Trotter Multiple Sclerosis Center
Saint Louis, MO
Saint Louis, MO
Columbia University Multiple Sclerosis Center
New York, NY
New York, NY
Mellen Center for MS Treatment & Research
Cleveland, OH
Cleveland, OH
OHSU Multiple Sclerosis Center
Portland, OR
Portland, OR
The Waddell Center for Multiple Sclerosis
Cincinnati, OH
Cincinnati, OH
Hackensack UMC Multiple Sclerosis Center
Paramus, NJ
Paramus, NJ
MS centers in Colorado
Compare treatment centers near a trial site by center type, providers and trials.
View Colorado centersMore Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.